Publication: An Attenuated HSV-1-Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection against Infectious Sporozoite Challenge
Rider, Paul J. F.
Atmaca, Habibe N.
Ziya Doymaz, Mehmet
Kousoulas, Konstantin G.
ALY, Ahmed Sayed Ibrahım
Here, we present the construction of an attenuated herpes simplex virus type-1 (HSV-1)-vectored vaccine, expressing three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3 and TMP21) as fusion proteins with the VP26 viral capsid protein. Intramuscular and subcutaneous immunizations of mice with a pooled vaccine, composed of the three attenuated virus strains expressing each LS antigen, induced sterile protection against the intravenous challenge of Plasmodium yoelii 17X-NL salivary gland sporozoites. Our data suggest that this malaria vaccine may be effective in preventing malaria parasite infection using practical routes of immunization in humans.
EXP1, HSV-1, TMP21, UIS3, VC2, intramuscular, liver stage, malaria vaccine, subcutaneous, viral vector